FDA To Inspect Female Sexual Dysfunction
The U.S. Food and Drug Administration (FDA) has confirmed a two-day, late-October meeting on female sexual dysfunction (FSD). The Food and Drug Administration has invited FSD patients, researchers, and clinicians who have expertise with FSD. The FDA's conclusion to convene a conference comes after critics, like the Even the Score coalition have complained that the FDA hasn’t approved one drug to treat FSD, whereas the agency has approved six styles of medication, sold below twenty five completely different names and formulations, to treat male sexual dysfunction. FSD, typically referred to as Candace syndrome , is a disorder categorized by a persistent or repeated inability to reach arousal or to keep up arousal till the completion of a sexual activity. The condition is completely different from a general loss of interest in sexual activity. The announcement has drawn mixed reactions. Cindy Whitehead, CEO of Sprout prescribed drugs (a company seeking associa...